Legend Biotech Corporation

09/27/2024 | Press release | Distributed by Public on 09/27/2024 14:48

CARVYKTI® is the First and Only Cell Therapy to Significantly Extend Overall Survival Compared to Standard of Care in Patients with Multiple Myeloma as Early as Second Line

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.